-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ABL-105 in Gastric Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ABL-105 in Gastric Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ABL-105 in Gastric Cancer Drug Details: ABL-105 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ABL-105 in Gastroesophageal (GE) Junction Carcinomas
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ABL-105 in Gastroesophageal (GE) Junction Carcinomas report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ABL-105 in Gastroesophageal (GE) Junction Carcinomas Drug Details: ABL-105 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ABL-105 in Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ABL-105 in Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ABL-105 in...
-
Sector Analysis
BCR-ABL Tests Market Size by Segments, Share, Regulatory, Reimbursement, and Forecast to 2033
BCR-ABL Tests Market Report Overview The BCR-ABL Tests market size was valued at $23.5 million in 2023. The market is expected to grow at a CAGR of more than 5% during 2023-2033. Breakpoint Cluster Region - Tyrosine-Protein Kinase ABL1 fusion gene (BCR-ABL) tests are carried out to detect fusion gene mutations in patient tissue samples. The outcome may guide therapies to treat various cancers including chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), and acute myelogenous leukemia (AML). BCR-ABL Tests...
-
Company Insights
Innovation and Patenting activity of ABL Bio Inc Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of ABL Bio Inc Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ABL-103 in Inflammation
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ABL-103 in Inflammation report and make more profitable business decisions. How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ABL-001 in Metastatic Biliary Tract Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. ABL-001 in Metastatic Biliary Tract Cancer Drug Details: ABL-001 (TR-009) is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ABL-001 in Extrahepatic Bile Duct Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. ABL-001 in Extrahepatic Bile Duct Cancer Drug Details: ABL-001 (TR-009) is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Olverembatinib in Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Olverembatinib in Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Olverembatinib in Chronic Myelocytic Leukemia (CML, Chronic...